AstraZeneca Calls for UK Govt Commitment to R&D Investment

The transcript discusses the UK's focus on innovation, particularly in life sciences, as highlighted in a recent speech by Richie Sunak. It emphasizes the importance of R&D investment and a stable regulatory environment post-Brexit. The commitment to UK investment is strong, with significant funding in R&D. The NHS faces challenges, but partnerships with the industry aim to improve care models and access to innovation. The potential for regulatory improvements post-Brexit is also explored.

What role does the partnership between the MHRA and NHS England play in innovation?

What challenges does the NHS face in terms of financial support?

What changes are needed to get new drugs to patients faster?